Podcasts about liver fibrosis

Send us a textWelcome back Rounds Table Listeners! We are back today with our Classic Rapid Fire Podcast! This week, Dr. John Fralick and guest host Dr. Chunpeng Nie discuss two recent papers: resmetirom for the treatment of Nonalcoholic Steatohepatitis (NASH)—now known as Metabolic Dysfunction-Associated Steatohepatitis (MASH)—with liver fibrosis, and the effect of a Mediterranean diet on disease activity, inflammation, and the gut microbiome in patients with ulcerative colitis. Two papers, here we go!A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (0:00 – 10:17)A Mediterranean Diet Pattern Improves Intestinal Inflammation Concomitant with Reshaping of the Bacteriome in Ulcerative Colitis: A Randomised Controlled Trial (10:18– 15:45)And for the Good Stuff:Shoutout to all the MTU teams supporting their R1's! (15:46 – 16:20).For the 1st time in Canada, surgeons put teeth in patients' eyes to restore sight (16:21 – 17:56)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Hannes Hagström discusses a study investigating the feasibility of screening for advanced liver fibrosis alongside retina scanning in people with type 2 diabetes.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00313-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Send us a textHappy Holidays Rounds Table Listeners! For our penultimate episode of 2024, we are back with a special treat! This week, Drs. Mike and John Fralick chat about the top five RCTs published over the past year:Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (0:00 – 3:40).Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (3:40 – 9:00).Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (9:00 – 13:55).Tirzepatide for Metabolic-Dysfunction Associated Steatohepatitis with Liver Fibrosis (13:55 – 20:00).Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (the Balance Trial) (20:00 – 23:30).And for the Good Stuff:Toronto Star Santa Claus Fund, Calgary Food Bank, Epilepsy Canada (23:30 – 24:51).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePodsSupport the show

Happy Holidays Rounds Table Listeners! For our penultimate episode of 2024, we are back with a special treat! This week, Drs. Mike and John Fralick chat about the top five RCTs published over the past year:Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (0:00 – 3:40).Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (3:40 – 9:00).Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (9:00 – 13:55).Tirzepatide for Metabolic-Dysfunction Associated Steatohepatitis with Liver Fibrosis (13:55 – 20:00).Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (the Balance Trial) (20:00 – 23:30).And for the Good Stuff:Toronto Star Santa Claus Fund, Calgary Food Bank, Epilepsy Canada (23:30 – 24:51).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

The FDA has issued a proposal to remove a common decongestant in over the counter products; A follow-up study assesses the efficacy of a schizophrenia treatment; The FDA's Endocrinologic and Metabolic Drugs Advisory Committee panel takes vote on the potential of approving a new diabetes treatment; IV ibuprofen adverse reactions examined; And semaglutide found to improve liver fibrosis.  

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo Nordisk's weight loss drug Wegovy showed significant improvement in liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis in a Phase III trial. Bristol Myers Squibb reported strong third-quarter results, while Regeneron had mixed sales results. Eli Lilly's third-quarter miss highlights their dependency on wholesaler stocking decisions. Lexicon lost an FDA advisory committee vote, and Merck lowered its full-year sales guidance despite strong Q3 results. Compass Pathways is laying off 30% of its employees. Novartis received FDA approval for Scemblix in certain CML patients. Opportunities for job seekers are available in the biotech industry.

Dr. Mitch Shulman can be heard every weekday morning at 7:50 on The Andrew Carter Morning Show.

Welcome back Rounds Table Listeners!We are back today with our Classic Rapid Fire Podcast!This week, Drs. John Fralick and Justin Boyle discuss two recent papers exploring the role of semaglutide in CKD in patients with Type II Diabetes and the utility of tirzepatide in metabolic dysfunction-associated steatohepatitis with liver fibrosis. Two papers, here we go!Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (0:00 – 09:32).Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (09:32 – 17:06).And for the Good Stuff:Congratulations to everyone starting/progressing through residency/finishing their training! (17:06 – 17:43).Calgary officials aiming for 'low end' of repair timeline after pipes arrive from San Diego (17:43 – 19:06).Questions? Comments? Feedback? We'd love to hear from you! @roundstable

BUFFALO, NY- July 10, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 12, entitled, “Aging exacerbates oxidative stress and liver fibrosis in an animal model of Down Syndrome.” Down Syndrome (DS) is a common genetic disorder characterized by an extra copy of chromosome 21, leading to dysregulation of various metabolic pathways. Oxidative stress in DS is associated with neurodevelopmental defects, neuronal dysfunction, and a dementia onset resembling Alzheimer's disease. Additionally, chronic oxidative stress contributes to cardiovascular diseases and certain cancers prevalent in DS individuals. In this new study, researchers Sebastiano Giallongo, Jessica Ferrigno, Rosario Caltabiano, Giuseppe Broggi, Amer M. Alanazi, Alfio Distefano, Emanuela Tropea, Antonella Tramutola, Marzia Perluigi, Giovanni Li Volti, Eugenio Barone, and Ignazio Alberto Barbagallo from the University of Catania, King Saud University, and Sapienza University of Rome investigated the impact of aging on oxidative stress and liver fibrosis using a DS murine model (Ts2Cje mice). “Our results show that DS mice show increased liver oxidative stress and impaired antioxidant defenses, as evidenced by reduced glutathione levels and increased lipid peroxidation.” DS liver exhibited an altered inflammatory response and mitochondrial fitness as the researchers showed by assaying the expression of HMOX1, CLPP, and the heat shock proteins Hsp90 and Hsp60. DS liver also displayed dysregulated lipid metabolism, indicated by altered expression of PPARα, PPARγ, FATP5, and CTP2. Consistently, these changes might contribute to non-alcoholic fatty liver disease development, a condition characterized by liver fat accumulation. Consistently, histological analysis of DS liver revealed increased fibrosis and steatosis, as showed by Col1a1 increased expression, indicative of potential progression to liver cirrhosis. Therefore, their findings suggest an increased risk of liver pathologies in DS individuals, particularly when combined with the higher prevalence of obesity and metabolic dysfunctions in DS patients. “These results shed a light on the liver's role in DS-associated pathologies and suggest potential therapeutic strategies targeting oxidative stress and lipid metabolism to prevent or mitigate liver-related complications in DS individuals.” DOI - https://doi.org/10.18632/aging.205970 Corresponding author - Giovanni Li Volti - livolti@unict.it Video short - https://www.youtube.com/watch?v=8GlAruy0xfk Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205970 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, Down Syndrome, oxidative stress, liver About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Fair Allocation of GLP-1 and Dual GLP-1–GIP Receptor Agonists 2.     Medical Assistant Health Coaching for Type 2 Diabetes in Primary Care 3.     Glycemic Control and Cognitive Aging 4.     Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis – 5.     Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?   For more information about each of ADA's science and medical journals, please visit www.diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

First-of-its-kind medication shows promise for liver disease patientsMetabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is estimated to affect nearly one-quarter of adults in the United States. Nonalcoholic steatohepatitis (NASH) is a form of MASLD that can cause liver fibrosis, cirrhosis, liver failure, and liver cancer. It is one of the most common reasons why patients need liver transplants.The FDA recently granted accelerated approval to resmetirom, the first medication to treat nonalcoholic steatohepatitis (NASH) and liver fibrosis. Prior to the FDA approval, there were no approved drugs to treat this diseaseIn this 5-minute check in, we review the promising phase 3 data from a randomized trial that led to FDA approval including the results, the implications for patient care, and the potential to transform the landscape of NASH managementGuest: Dr. Justin Reynolds, Associate Professor, Creighton University School of Medicine, Gastroenterologist and Transplant Hepatologist, St Joseph's Hospital and Medical Center Transplant Center in Phoenix, Arizona.Study: https://www.nejm.org/doi/10.1056/NEJMoa2309000

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis 2.     Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes 3.     Improved Glycemic Outcomes With Diabetes Technology Use Independent of Socioeconomic Status in Youth With Type 1 Diabetes 4.     Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity 5.     Epidemiology and Prognostic Implications of Coronary Artery Calcium in Asymptomatic Individuals With Prediabetes   For more information about each of ADA's science and medical journals, please visit www.diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies. Presenters:Arun B. Jesudian, MDAssociate Professor of Clinical MedicineDivision of Gastroenterology and HepatologyWeill Cornell MedicineNew York, New YorkMazen Noureddin, MD, MHScProfessor of MedicineHouston Methodist HospitalDirector Houston Research InstituteHouston, TexasContent based on an online CME program supported by independent educational grants from Novo Nordisk.To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.Link to full program:https://bit.ly/3Tyu7At

In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies. Presenters:Arun B. Jesudian, MDAssociate Professor of Clinical MedicineDivision of Gastroenterology and HepatologyWeill Cornell MedicineNew York, New YorkMazen Noureddin, MD, MHScProfessor of MedicineHouston Methodist HospitalDirector Houston Research InstituteHouston, TexasContent based on an online CME program supported by independent educational grants from Novo Nordisk.To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.Link to full program:https://bit.ly/3Tyu7At

This week, Paul talks to Mike Fave, critical care RN, about all things sugar & fructose. They share their thoughts on a recent podcast with Andrew Huberman and Alex Lustig, and why they disagree with certain points made about insulin, fruit juice, and fructose. 00:00:00 Podcast begins 00:04:00 Mike's background 00:05:15 Diving into fructose 00:13:00 Thoughts on honey and other carb sources 00:27:30 Robert Lustig rebuttal: is fructose addictive? 00:37:40 Fructose & fiber 00:47:00 How fructose affects the mitochondria 00:51:00 Clarifying hyperglycemia vs. a postprandial hyperglycemia 00:56:17 Is insulin the bad guy? 01:12:20 How insulin relates to diabetes, obesity, and insulin resistance 01:23:30 Balancing protein, fat and carbohydrates 01:30:00 Is fructose making us fat? 01:46:00 Final thoughts Connect with Mike: Mikefave.com https://m.youtube.com/@MikeFaveSimplified References: Review article: fructose malabsorption and the bigger picture: https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2006.03186.x A Relationship between Reduced Nucleus Accumbens Shell and Enhanced Lateral Hypothalamic Orexin Neuronal Activation in Long-Term Fructose Bingeing Behavior: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988143/ A High-Fat Meal, or Intraperitoneal Administration of a Fat Emulsion, Increases Extracellular Dopamine in the Nucleus Accumbens: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061790/ A Relationship between Reduced Nucleus Accumbens Shell and Enhanced Lateral Hypothalamic Orexin Neuronal Activation in Long-Term Fructose Bingeing Behavior: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988143/ The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents: https://journals.physiology.org/doi/full/10.1152/ajpendo.00165.2014?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org Consumption of Raw Orange, 100% Fresh Orange Juice, and Nectar- Sweetened Orange Juice—Effects on Blood Glucose and Insulin Levels on Healthy Subjects: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770506/ The Effects of Soluble Dietary Fibers on Glycemic Response: An Overview and Futures Perspectives: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736284/#B37-foods-11-03934 The Effects of Soluble Dietary Fibers on Glycemic Response: An Overview and Futures Perspectives: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736284/#B37-foods-11-03934 Formation of Fructose-Mediated Advanced Glycation End Products and Their Roles in Metabolic and Inflammatory Diseases: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5227984/ Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM: https://pubmed.ncbi.nlm.nih.gov/9216960/ Glucagon and type 2 diabetes: the return of the alpha cell: https://pubmed.ncbi.nlm.nih.gov/25344790/ Insulin, growth hormone and sport: https://pubmed.ncbi.nlm.nih.gov/11431133/ Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881846/ Fructose metabolism in humans – what isotopic tracer studies tell us: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533803/ Absorption capacity of fructose in healthy adults. Comparison with sucrose and its constituent monosaccharides: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1433856/ Review article: fructose malabsorption and the bigger picture: https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2006.03186.x Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice: https://pubmed.ncbi.nlm.nih.gov/19637282/ Fructose Promotes Leaky Gut, Endotoxemia and Liver Fibrosis through CYP2E1-Mediated Oxidative and Nitrative Stress: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783321/

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.07.29.551032v1?rss=1 Authors: Sun, C., Zhou, C., Daneshvar, K., Kratkiewicz, A. J., Ben Saad, A., Hess, A., Chen, J. Y., Pondick, J. V., York, S. R., Li, W., Moran, S. P., Gentile, S., Ur Rahman, R., Li, Z., Sparks, R., Habboub, T., Kim, B.-M., Choi, M., Affo, S., Schwabe, R. F., Popov, Y. V., Mullen, A. C. Abstract: Background & Aims: Fibrosis is the common endpoint for all forms of chronic liver injury, and progression of fibrosis leads to the development of end-stage liver disease. Activation of hepatic stellate cells (HSCs) and their transdifferentiation to myofibroblasts results in the accumulation of the extracellular matrix (ECM) proteins that form the fibrotic scar. Long noncoding (lnc) RNAs regulate the activity of HSCs and may provide targets for fibrotic therapies. Methods: We identified lncRNA TILAM as expressed near COL1A1 in human HSCs and performed loss-of-function studies in human HSCs and liver organoids. Transcriptomic analysis of HSCs isolated from mice defined the murine ortholog of TILAM. We then generated Tilam-deficient GFP reporter mice and quantified fibrotic responses to carbon tetrachloride (CCl4) and choline-deficient L-amino acid defined high fat diet (CDA-HFD). Co-precipitation studies, mass spectrometry, and gene expression analyses identified protein partners of TILAM. Results: TILAM is conserved between human and mouse HSCs and regulates expression of ECM proteins, including collagen. Tilam is selectively induced in murine HSCs during the development of fibrosis in vivo. In both male and female mice, loss of Tilam results in reduced fibrosis in the setting of CCl4 and CDA-HFD injury models. TILAM interacts with promyelocytic leukemia protein (PML) to stabilize PML protein levels and promote the fibrotic activity of HSCs. Conclusion: TILAM is activated in HSCs and interacts with PML to drive the development of liver fibrosis. Depletion of TILAM may serve as a therapeutic approach to combat the development of end stage liver disease. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

STUDIES REFERENCED   ROLE OF SCALP BIOPSIES IN BLACK WOMEN WITH HAIR LOSS   Douglas A et al. Scalp Biopsy Influences Diagnostic Accuracy and Treatment in Black Women with Alopecia: A Retrospective Study. J Am Acad Dermatol. 2023 Jan 31;S0190-9622(23)00157-3.    ORAL MINOXIDIL IN CHEMOTHERAPY RELATED HAIR LOSS   Kang J et al. Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study. J Am Acad Dermatol 2022 Dec 13;S0190-9622(22)03261-3.     FOLLICULOTROPIC MYCOSIS FUNGOIDES   Paolino G et al. Widespread and eruptive comedonal lesions with alopecia. JAAD Case Rep . 2022 Nov 1;31:23-26.  Kreutzer and Effendy. Cicatricial Alopecia Related to Folliculotropic Mycosis Fungoides. Dermatol Ther (Heidelb). 2020 Oct;10(5):1175-1180 Gallo G et al Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement. Scientific Reports.  2021 May 18;11(1):10555.     ATRICHIA WITH PAPULES LESIONS   Boisen J et al. Atrichia With Papular Lesions Confirmed via Genetic Testing: A Case Report. Cureus 2022 Dec; 14(12): e32562. Zlotogorski A, Panteleyev AA, Aita VM, Christiano AM. Clinical and molecular diagnostic criteria of congenital atrichia with papular lesions. J Invest Dermatol 2002; 118: 887–890 Yip L, Horev L, Sinclair R, et al. Atrichia with papular lesions: a report of three novel human hairless gene mutations and a revision of diagnostic criteria. Acta Derm Venereol 2008; 88(4): 346–349. Bergman R et al. The alopecias associated with vitamin D-dependent rickets type IIA and with hairless gene mutations: a comparative clinical, histologic, and immunohistochemical study. Arch Dermatol. 2005 Mar;141(3):343-51.     METHOTREXATE AND LIVER FIBROSIS Atallah  E et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. J Hepatol . 2023 Jan 23;S0168-8278(23)00020-X.   Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum 2015;45(2):156–162   Cheema HI et al. Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis. J Investig Med. 2022 Oct;70(7):1452-1460.

New tools are available to assess your patients for liver fibrosis; listen as our experts discuss how to screen in the clinic. Credit available for this activity expires: 12/20/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/985714?ecd=bdc_podcast_libsyn_mscpedu

Today we are continuing our conversation on altered intestinal permeability – aka leaky gut. We are diving deep, once again, my friends, deep, into testing and also management for altered intestinal permeability. Kick back and relax – I think you are going to really enjoy this one. Just a quick disclaimer that this podcast is meant for educational purposes only and is not meant to diagnose or be a substitute for medical advice from your practitioner. **Follow me on Instagram: https://www.instagram.com/thefunctionalnursepractitioner/ ** Level up your products: https://www.ewg.org/ewgverified/ **Interesting articles for more information** The Leaky Gut: Mechanisms, Measurement and Clinical Implications in Humans: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790068/pdf/nihms-1054015.pdf All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases [version 1; peer review: 3 approved]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996528/pdf/f1000research-9-22543.pdf Leaky Gut As a Danger Signal for Autoimmune Diseases: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440529/pdf/fimmu-08-00598.pdf Fructose Promotes Leaky Gut, Endotoxemia and Liver Fibrosis through CYP2E1-Mediated Oxidative and Nitrative Stress: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783321/pdf/nihms-1023086.pdf The use of biomarkers associated with leaky gut as a diagnostic tool for early intervention in autism spectrum disorder: a systematic review: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439029/pdf/13099_2021_Article_448.pdf The Role of the Gastrointestinal Mucus System in Intestinal Homeostasis: Implications for Neurological Disorders: https://www.frontiersin.org/articles/10.3389/fcimb.2020.00248/full Is There an Exercise-Intensity Threshold Capable of Avoiding the Leaky Gut?: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982409/pdf/fnut-08-627289.pdf Downregulated Gene Expression Spectrum and Immune Responses Changed During the Disease Progression in Patients With COVID-19: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188184/ Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604320/pdf/fncel-09-00392.pdf Intestinal Microbiome, Akkermansia muciniphila, and Medical Nutrition Therapy: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5145007/pdf/14-16.pdf

When it comes to managing adults with HBV, should age factor into your treatment decision—or is it important to treat everyone, regardless of age?Listen as Dr George Lau discusses these questions and more for strategizing the monitoring and treatment of older adults with HBV. Presenter: George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA)ChairmanHumanity and Health Medical GroupHong Kong, ChinaChair, Professor, and Co-DirectorLiver Diseases & Transplant CentreThe Fifth Medical Centre of Chinese PLA General HospitalBeijing, ChinaLink to full program:https://bit.ly/3fg9fwB

Today we're going to be talking about a vitally important topic - intestinal permeability. You may not have heard this term, but you likely have heard the term that's all over social media - leaky gut. You guys are really gonna love this one. This is part one in a two part series. In next week's episode we will get more into testing for leaky gut and different management strategies. Just a quick disclaimer that this podcast is meant for educational purposes only and is not meant to diagnose or be a substitute for medical advice from your practitioner. **Follow me on Instagram: https://www.instagram.com/thefunctionalnursepractitioner/ ** Level up your products: https://www.ewg.org/ewgverified/ **Interesting articles for more information** The Leaky Gut: Mechanisms, Measurement and Clinical Implications in Humans: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790068/pdf/nihms-1054015.pdf All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases [version 1; peer review: 3 approved]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996528/pdf/f1000research-9-22543.pdf Leaky Gut As a Danger Signal for Autoimmune Diseases: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440529/pdf/fimmu-08-00598.pdf Fructose Promotes Leaky Gut, Endotoxemia and Liver Fibrosis through CYP2E1-Mediated Oxidative and Nitrative Stress: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783321/pdf/nihms-1023086.pdf The use of biomarkers associated with leaky gut as a diagnostic tool for early intervention in autism spectrum disorder: a systematic review: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439029/pdf/13099_2021_Article_448.pdf The Role of the Gastrointestinal Mucus System in Intestinal Homeostasis: Implications for Neurological Disorders: https://www.frontiersin.org/articles/10.3389/fcimb.2020.00248/full Is There an Exercise-Intensity Threshold Capable of Avoiding the Leaky Gut?: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982409/pdf/fnut-08-627289.pdf Downregulated Gene Expression Spectrum and Immune Responses Changed During the Disease Progression in Patients With COVID-19: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188184/ Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604320/pdf/fncel-09-00392.pdf Intestinal Microbiome, Akkermansia muciniphila, and Medical Nutrition Therapy: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5145007/pdf/14-16.pdf

When it comes to managing older adults with hepatitis B virus (HBV), what comorbidity, comedication, and adherence issues should be considered?Listen as Graham R. Foster, FRCP, PhD, discusses these considerations and more for strategizing the monitoring and treatment of older adults with HBV. Presenter: Graham R. Foster, FRCP, PhDProfessor of HepatologyThe Liver UnitConsultant HepatologistQueen Mary University of LondonLondon, United KingdomLink to full program:https://bit.ly/3fg9fwB

How do we define “older” in our older patients living with hepatitis B virus (HBV)? What monitoring and treatment options should be considered for these older patients with chronic HBV infection?Listen as Nancy Reau, MD, discusses strategies and considerations for monitoring and treating older adults with HBV, illustrated with a patient case.Presenter:Nancy Reau, MDProfessor of MedicineChief, Section of Hepatology  Associate Director, Solid Organ Transplantation  Richard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisLink to full program:https://bit.ly/3T1UImw

To obtain credit – Click Here For more information – Click Here

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Maurizio Bonacini, MD What non-invasive techniques are available to assess liver fibrosis? Joining Dr. Peter Buch to give us insight on this key question, along with how we can incorporate these treatments into our patient care, is Dr. Maurizio Bonacini. Dr. Bonacini is an Associate Professor of Clinical Medicine at the University of California, San Francisco and CEO of Mission Gastroenterology and Hepatology.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Maurizio Bonacini, MD What non-invasive techniques are available to assess liver fibrosis? Joining Dr. Peter Buch to give us insight on this key question, along with how we can incorporate these treatments into our patient care, is Dr. Maurizio Bonacini. Dr. Bonacini is an Associate Professor of Clinical Medicine at the University of California, San Francisco and CEO of Mission Gastroenterology and Hepatology.

The Journal of Rheumatology's Editor-in-Chief Earl Silverman discusses this month's selection of articles that are most relevant to the clinical rheumatologist. Included is an excerpt from this month's Editor's Picks spotlight interview with authors Yasaman Emad, Nicola Dalbeth, John Weinman, Trudie Chalder and Keith J. Petrie about their article "Why Do Patients With Gout Not Take Allopurinol?" -doi.org/10.3899/jrheum.210950 This month's selections also include: Using FibroScan to Assess for the Development of Liver Fibrosis in Patients With Arthritis on Methotrexate: A Single-center Experience - doi.org/10.3899/jrheum.211281 Central Obesity in Axial Spondyloarthritis: The Missing Link to Understanding Worse Outcomes in Women? - doi.org/10.3899/jrheum.211062 The Challenge of Addressing the Rheumatology Workforce Shortage - doi.org/10.3899/jrheum.220300 Association of Health Literacy and Numeracy With Lupus Knowledge and the Creation of the Lupus Knowledge Assessment Test - doi.org/10.3899/jrheum.210708 Why Do Patients With Gout Not Take Allopurinol? - doi.org/10.3899/jrheum.210950 Dr. Li et al reply - doi.org/10.3899/jrheum.211185 To read these, and other full articles visit www.jrheum.org. Music by David Hilowitz

Episode 10 dives into recent NAFLD and NASH Prevalence studies in the US, UK and Germany and explores what this can tell us about who to screen for NAFLD and NASH, when to screen first and how often to screen after that. This conversation focuses on the paper Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany, which was published last Saturday in Hepatology Communications. Last author Jörn Schattenberg presents results of the paper, after which panelist Ian Rowe and Wayne Eskridge ask the role that FIB-4 played in the study and analysis and Roger Green asks Professor Schattenberg what significance to apply to a Fatty Liver Index >60 in 3/8 of the sample.

In this episode, Jürgen K. Rockstroh, MD, and Giada Sebastiani, MD, discuss key strategies to appropriately screen for, identify, and manage nonalcoholic steatohepatitis in persons with HIV. They also answer pressing questions from healthcare professionals.Presenters: Jürgen K. Rockstroh, MDProfessor of MedicineUniversity Hospital BonnDepartment of Medicine IBonn, GermanyGiada Sebastiani, MDAssociate Professor of MedicineMcGill University Health CentreDivision of Gastroenterology and Hepatology and Division of Infectious DiseasesClinician ScientistResearch Institute of McGill University Health CentreMontreal, Quebec, CanadaContent based on an online CME program supported by an educational grant from Theratechnologies Inc.Link to full program:https://bit.ly/363orZ9

In this episode, Jürgen K. Rockstroh, MD, discusses his recommended approach for diagnosing nonalcoholic steatohepatitis in patients with HIV, the value of noninvasive diagnostic tests such as serum biomarkers and elastography, and how timely nonalcoholic fatty liver disease assessment and metabolic risk factor determination can result in early interventions.Presenter:Jürgen K. Rockstroh, MDProfessor of MedicineUniversity Hospital BonnDepartment of Medicine IBonn, GermanyContent based on an online CME program supported by an educational grant from Theratechnologies Inc.Link to full program:https://bit.ly/3Gk7juJ

In this episode, hepatologist Giada Sebastiani, MD, discusses why the presence of obesity, metabolic syndrome, persistent elevation of ALT, or exposure to dideoxynucleoside analogues can trigger an evaluation for NAFLD and NASH, particularly in our aging population of patients with HIV with topics including:Metabolic factors  HIV-related factorsWhich patients with HIV are at riskPresenter:Giada Sebastiani, MDAssociate Professor of MedicineMcGill University Health CentreDivision of Gastroenterology and Hepatology and Division of Infectious DiseasesClinician ScientistResearch Institute of McGill University Health CentreMontreal, Quebec, CanadaContent based on an online CME program supported by an educational grant from Theratechnologies Inc.Link to full program: https://bit.ly/3BYoXBP

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 20 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. This issue will review: Time in Range and Mortality  Prevalence of Liver Fibrosis in Patients With T2DM  Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New- Onset T2DM  Glycemic Control and Risk of Cellulitis  Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction  Association of Serum 25-Hydroxyvitamin D Concentrations With All-Cause and Cause-Specific Mortality Among Individuals With Diabetes  For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Richard Sterling, MD, MSc, FACP, FACG, AGAF, FAASLD Non-invasive assessments of liver fibrosis can be subcategorized into many different tests. What do we need to know about these increasingly popular assessments? Dr. Peter Buch is joined by Dr. Richard Sterling, professor of medicine at Virginia Commonwealth University to discuss when it is appropriate to use each of these assessments for patients with liver fibrosis.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Richard Sterling, MD, MSc, FACP, FACG, AGAF, FAASLD Non-invasive assessments of liver fibrosis can be subcategorized into many different tests. What do we need to know about these increasingly popular assessments? Dr. Peter Buch is joined by Dr. Richard Sterling, professor of medicine at Virginia Commonwealth University to discuss when it is appropriate to use each of these assessments for patients with liver fibrosis.

Podcast Contents 00:00-3:55- Introduction by David A. Bluemke, MD, PhD, Editor of Radiology.   03:56-10:10– Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database. Berg et al. Radiology 2020; 296:32–41. [Full Text]   10:11- 15:50 –PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. Tan et al. Radiology 2020; 296:44–55. [Full Text]    15"51- 21:32 - Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis.  Zhou et al. Radiology 2020; 296:67–75. [Full Text]    21:33- 26:58– Dentate Nucleus Signal Intensity Increases Following Repeated Gadobenate Dimeglumine Administrations: A Retrospective Analysis. Nguyen et al. Radiology 2020; 296:122–130. [Full Text]   26:59-27:32– Conclusion by David A. Bluemke, MD, PhD, Editor of Radiology

Audible Article by Shilpa Tiwari‐Heckler and Z. Gordon Jiang

In this episode Dr. Meng will discuss how they triaged patients using the Fibrosis 4 Index for Liver Fibrosis. For the complete abstract visit JCAG the online Journal of the Canadian Association of Gastroenterology 2019 Volume 2, Issue Supplement_2, 15 March 2019, Page 387 https://academic.oup.com/jcag/issue/2/Supplement_2 This episode was recorded during the 2019 Gastroenterology Residents-in-Training (GRIT) Program in Banff, Alberta.

Meet Mark Black and listen as he shares his story with unmatched transparency. He shares how alcohol has caused damage to his liver and how he is using cannabis to aid his new direction in life and his desire to see his daughter grow up. We have all made bad choices in the past, but we all deserve a second chance at living our best life. 

David A. Bluemke, MD, PhD, Editor of Radiology discusses three research articles from the July 2018 issue of Radiology. ARTICLES DISCUSSED Summary of US Time-Harmonic Elastography: Detection of Liver Fibrosis in Adolescents with Extreme Obesity with Nonalcoholic Fatty Liver Disease. Radiology 2018; 288(1):99-106. Summary of General Practitioners Referring Adults to MR Imaging for Knee Pain: A Randomized Controlled Trial to Assess Cost-effectiveness. Radiology 2018; 2018; 288(1):170-176. Summary of Radiation Dose Reduction by Using CT with Iterative Model Reconstruction in Patients with Pulmonary Invasive Fungal Infection. Radiology 2018; 2018; 288(1):285-292.

Audible Article by Tamir Diamond and Nadia Ovchinsky

Audible Article by Tamir Diamond and Nadia Ovchinsky

David A. Bluemke, MD, PhD, Editor of Radiology discusses four research articles from the May 2018 issue of Radiology. ARTICLES DISCUSSED Summary of CM-101: Type I Collagen-targeted MR Imaging Probe for Detection of Liver Fibrosis. Radiology 2018;287(2):581-589. Summary of What Patients Want to Know about Imaging Examinations: A Multiinstitutional U.S. Survey in Adult and Pediatric Teaching Hospitals on Patient Preferences for Receiving Information before Radiologic Examinations. Radiology 2018;287(2):554-562. Summary of Changes in Primary Care Health Care Utilization after Inclusion of Epidemiologic Data in Lumbar Spine MR Imaging Reports for Uncomplicated Low Back Pain. Radiology 2018;287(2):563-569. Summary of Psychoradiologic Utility of MR Imaging for Diagnosis of Attention Deficit Hyperactivity Disorder: A Radiomics Analysis. Radiology 2018;287(2):620-630.

In this episode Mairi McLean, Education Editor for Gut, talks to Dr Katja Breitkopf-Heinlein, Medical Faculty Mannheim, Heidelberg University, about her recently published paper "BMP-9 interferes with liver regeneration and promotes liver fibrosis". Full paper >> http://gut.bmj.com/content/66/5/939

Pere Ginès from the Liver Unit at the Hospital Clinic in Barcelona, Spain, discusses a Viewpoint for liver fibrosis screening in the general population.

Pere Ginès from the Liver Unit at the Hospital Clinic in Barcelona, Spain, discusses a Viewpoint for liver fibrosis screening in the general population.

In this interview, Dr Navasa from the Hospital Clinic Barcelona discusses how his team is using the Siemens ADVIA Centaur® Enhanced Liver Fibrosis (ELFTM) Test, in conjunction with advanced imaging techniques for the non-invasive assessment of liver fibrosis. The recent introduction of these advanced tools is enabling physicians to more closely monitor disease progression and adjust treatment strategies accordingly. Like this episode? Join the SelectScience community of healthcare professionals and get free access to more articles, videos, product directories and news at www.selectscience.net/clinical-diagnostics.

Dr. Florence Wong discusses her manuscript "New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection." Click http://bit.ly/1bzQ8Cq to access the abstract.

Dr. Stephen Harrison talks to Drs. Thomas Wirth and Yoshiaki Suname about the paper: Hepatic activation of IKK/NFκB signaling induces liver fibrosis via macrophage-mediated chronic inflammation Abstract: Liver damage in humans is induced by various insults including alcohol abuse, hepatitis B/C virus infection, autoimmune or metabolic disorders and, when persistent, leads to development of liver fibrosis. Because the nuclear factor-κB (NF-κB) system is activated in response to several of these stresses, we hypothesized that NF-κB activation in hepatocytes may contribute to fibrosis development. To activate the NF-κB signaling pathway in a time- and cell-type-specific manner in the liver, we crossed transgenic mice carrying the tetracycline-responsive transactivator under the control of the liver activator protein promotor with transgenic mice carrying a constitutively active form of the Ikbkb gene (IKK2 protein [CAIKK2]). Double-transgenic mice displayed doxycycline-regulated CAIKK2 expression in hepatocytes. Removal of doxycycline at birth led to activation of NF-κB signaling, moderate liver damage, recruitment of inflammatory cells, hepatocyte proliferation, and ultimately to spontaneous liver fibrosis development. Microarray analysis revealed prominent up-regulation of chemokines and chemokine receptors and this induction was rapidly reversed after switching off the CAIKK2 expression. Turning off the transgene expression for 3 weeks reversed stellate cell activation but did not diminish liver fibrosis. The elimination of macrophages by clodronate-liposomes attenuated NF-κB-induced liver fibrosis in a liver-injury-independent manner. Conclusion: Our results revealed that hepatic activation of IKK/NF-κB is sufficient to induce liver fibrosis by way of macrophage-mediated chronic inflammation. Therefore, agents controlling the hepatic NF-κB system represent attractive therapeutic tools to prevent fibrosis development in multiple chronic liver diseases. (HEPATOLOGY 2012;56:1117–1128)

Aachen: Vortrag im TRR-57-Seminar